TENAX THERAPEUTICS, INC.
About TENAX THERAPEUTICS, INC.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$52.6M
- Total assets
- $104.2M
- Market cap
- $284.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $56.4M
- Operating income
- -$56.4M
- Income tax
- $0
- Net income
- -$52.6M
- EPS (basic)
- $-1.34
- EPS (diluted)
- $-1.34
Balance sheet
- Total assets
- $104.2M
- Current assets
- $104.2M
- Total liabilities
- $7.2M
- Current liabilities
- $7.2M
- Shareholders’ equity
- $97.1M
Cash flow
- Operating cash flow
- -$35.8M
- Investing cash flow
- -$2.7M
- Financing cash flow
- $38.5M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $284.6M
- EPS (diluted)
- $-1.34
- Shares outstanding
- 27.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 1, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $52.6M in FY2025.
- Trading 42% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TENAX THERAPEUTICS, INC..
Write a review
News about TENAX THERAPEUTICS, INC.
News & sentiment via Polygon.io
